BIOMARIN PHARMACEUTICAL INC Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $563.00 thousand for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2018-02-26
- BIOMARIN PHARMACEUTICAL INC adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-09-30 was $249.00K.
- BIOMARIN PHARMACEUTICAL INC adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-06-30 was $215.00K.
- BIOMARIN PHARMACEUTICAL INC adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-03-31 was $99.00K.
- BIOMARIN PHARMACEUTICAL INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $2.19M, a 46.88% increase from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $1.49M, a 103.41% increase from fiscal 2013.
- BIOMARIN PHARMACEUTICAL INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $733.00K, a 54.97% increase from fiscal 2012.
- BIOMARIN PHARMACEUTICAL INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2012 was $473.00K, a 13.98% increase from fiscal 2011.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|---|---|---|
| 2016-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $464.00K derived: sum of 2 quarters · filed 2016-11-03 | $563.00K 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $314.00K 10-Q · filed 2016-08-08 | ||
| 2016-03-31 | $99.00K 10-Q · filed 2016-05-02 | |||
| 2015-12-31 | $2.19M 10-K · filed 2018-02-26 | |||
| 2014-12-31 | $1.49M 10-K · filed 2017-02-27 | |||
| 2013-12-31 | $733.00K 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $473.00K 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $415.00K 10-K · filed 2014-02-26 | |||
| 2010-12-31 | $541.00K 10-K · filed 2013-02-26 | |||
| 2009-12-31 | $113.00K 10-K · filed 2012-02-22 | |||
| 2008-12-31 | $960.00K 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |